These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 31053170)
1. Effects of neprilysin-renin inhibition in comparison with neprilysin-angiotensin inhibition on the neurohumoral changes in rats with heart failure. Dizaye K; Ali RH BMC Pharmacol Toxicol; 2019 May; 20(1):23. PubMed ID: 31053170 [TBL] [Abstract][Full Text] [Related]
2. B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial. Myhre PL; Vaduganathan M; Claggett B; Packer M; Desai AS; Rouleau JL; Zile MR; Swedberg K; Lefkowitz M; Shi V; McMurray JJV; Solomon SD J Am Coll Cardiol; 2019 Mar; 73(11):1264-1272. PubMed ID: 30846338 [TBL] [Abstract][Full Text] [Related]
4. Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study. Nougué H; Pezel T; Picard F; Sadoune M; Arrigo M; Beauvais F; Launay JM; Cohen-Solal A; Vodovar N; Logeart D Eur J Heart Fail; 2019 May; 21(5):598-605. PubMed ID: 30520545 [TBL] [Abstract][Full Text] [Related]
5. Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial. DeVore AD; Braunwald E; Morrow DA; Duffy CI; Ambrosy AP; Chakraborty H; McCague K; Rocha R; Velazquez EJ; JAMA Cardiol; 2020 Feb; 5(2):202-207. PubMed ID: 31825471 [TBL] [Abstract][Full Text] [Related]
6. Effect of additive renin inhibition with aliskiren on renal blood flow in patients with Chronic Heart Failure and Renal Dysfunction (Additive Renin Inhibition with Aliskiren on renal blood flow and Neurohormonal Activation in patients with Chronic Heart Failure and Renal Dysfunction). Schroten NF; Damman K; Hemmelder MH; Voors AA; Navis G; Gaillard CA; van Veldhuisen DJ; Van Gilst WH; Hillege HL Am Heart J; 2015 May; 169(5):693-701.e3. PubMed ID: 25965717 [TBL] [Abstract][Full Text] [Related]
7. Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure. Damman K; Gori M; Claggett B; Jhund PS; Senni M; Lefkowitz MP; Prescott MF; Shi VC; Rouleau JL; Swedberg K; Zile MR; Packer M; Desai AS; Solomon SD; McMurray JJV JACC Heart Fail; 2018 Jun; 6(6):489-498. PubMed ID: 29655829 [TBL] [Abstract][Full Text] [Related]
8. Beneficial cardiac effects of the renin inhibitor aliskiren in spontaneously hypertensive rats. van Esch JH; Moltzer E; van Veghel R; Garrelds IM; Leijten F; Bouhuizen AM; Danser AH J Hypertens; 2010 Oct; 28(10):2145-55. PubMed ID: 20625318 [TBL] [Abstract][Full Text] [Related]
10. Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial. Jhund PS; Claggett B; Packer M; Zile MR; Voors AA; Pieske B; Lefkowitz M; Shi V; Bransford T; McMurray JJ; Solomon SD Eur J Heart Fail; 2014 Jun; 16(6):671-7. PubMed ID: 24692284 [TBL] [Abstract][Full Text] [Related]
11. Spotlight on valsartan-sacubitril fixed-dose combination for heart failure: the evidence to date. Vilela-Martin JF Drug Des Devel Ther; 2016; 10():1627-39. PubMed ID: 27274196 [TBL] [Abstract][Full Text] [Related]
12. Hemodynamic and hormonal changes to dual renin-angiotensin system inhibition in experimental hypertension. Moniwa N; Varagic J; Ahmad S; VonCannon JL; Simington SW; Wang H; Groban L; Brosnihan KB; Nagata S; Kato J; Kitamura K; Gomez RA; Lopez ML; Ferrario CM Hypertension; 2013 Feb; 61(2):417-24. PubMed ID: 23232645 [TBL] [Abstract][Full Text] [Related]
14. Impact of Sacubitril-Valsartan on Markers of Glomerular Function. Tersalvi G; Dauw J; Martens P; Mullens W Curr Heart Fail Rep; 2020 Aug; 17(4):145-152. PubMed ID: 32488503 [TBL] [Abstract][Full Text] [Related]
15. Neprilysin inhibition with sacubitril/valsartan in the treatment of heart failure: mortality bang for your buck. Ansara AJ; Kolanczyk DM; Koehler JM J Clin Pharm Ther; 2016 Apr; 41(2):119-27. PubMed ID: 26992459 [TBL] [Abstract][Full Text] [Related]
16. Switching from ramipril to sacubitril/valsartan favorably alters electrocardiographic indices of ventricular repolarization in heart failure with reduced ejection fraction. Okutucu S; Sabanoglu C; Yetis Sayin B; Aksoy H; Bursa N; Oto A Acta Cardiol; 2020 Feb; 75(1):20-25. PubMed ID: 30513267 [No Abstract] [Full Text] [Related]
17. Angiotensin converting enzyme and neprilysin inhibition alter pain response in dexhamethasone-induced hypertensive rats. Aykan DA; Koca TT; Yaman S; Eser N Pharmacol Rep; 2019 Apr; 71(2):306-310. PubMed ID: 30826571 [TBL] [Abstract][Full Text] [Related]
18. Rationale and methods of the Prospective Study of Biomarkers, Symptom Improvement, and Ventricular Remodeling During Sacubitril/Valsartan Therapy for Heart Failure (PROVE-HF). Januzzi JL; Butler J; Fombu E; Maisel A; McCague K; Piña IL; Prescott MF; Riebman JB; Solomon S Am Heart J; 2018 May; 199():130-136. PubMed ID: 29754651 [TBL] [Abstract][Full Text] [Related]